{
    "clinical_study": {
        "@rank": "124653", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "Inhaled Nitric Oxide will be delivered through the INOpulse\u00ae at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this program is to evaluate the logistic issues and patient requirements for\n      chronic pulsed INOmax delivery in ambulatory, home-care patients.  To understand patient\n      needs, patients with a variety of underlying diseases will be included.  Safety of chronic\n      therapy will be monitored by serial measurements of methemoglobin, platelet function assay\n      and reported adverse events."
        }, 
        "brief_title": "Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide", 
        "completion_date": {
            "#text": "December 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pulmonary Hypertension", 
            "Lung Disease", 
            "Sickle Cell Disease", 
            "Cardiac Transplant", 
            "Lung Transplant"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia, Sickle Cell", 
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Lung Diseases", 
                "Pulmonary Heart Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will help develop a comprehensive home care program using INOmax delivery\n      systems. This study will enroll a limited number of patients (5-7) from several disease\n      categories in order to develop the experience with testing acute and chronic responsiveness\n      to INO therapy.  The following groups will be tested:\n\n        1. Primary pulmonary hypertension (PPH)\n\n        2. Severe pulmonary hypertension due to congenital (anatomic) heart disease\n\n        3. Pulmonary hypertension or severe impairment of gas exchange in infants and children\n           with chronic lung disease\n\n        4. Pulmonary hypertension or severe impairment of gas exchange due to severe chronic lung\n           disease in adults\n\n        5. Pulmonary hypertension or severe impairment of gas exchange in hematologic and\n           transplant disorders - young children and adults with sickle cell disease, chronic lung\n           disease after bone marrow transplant, cardiac transplant, or lung transplant"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with pulmonary arterial hypertension (PAH) as defines by a mean pulmonary\n             artery pressure (PAP) of 25 mmHg or greater by cardiac catheterization within the\n             previous 12 months AND/OR Patients with chronic lung disease with severe impairment\n             of gas exchange unresponsive to conventional medical management.\n\n          -  If patient is receiving prostacyclin infusion treatment it must have been started at\n             least one  month prior to starting INO therapy. Patients will not be withdrawn from\n             the study if started on other medications for treatment of pulmonary hypertension.\n\n          -  Ability to establish a clinical investigator and a drug shipment site in the local\n             area.\n\n        Exclusion Criteria:\n\n          -  The Principal Investigator has determined that the patient and/or caregiver is/are\n             unable to manage safe administration of home nitric oxide therapy and maintain\n             appropriate drug accountability and storage.\n\n          -  Women who are pregnant or nursing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 10, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00041574", 
            "org_study_id": "INOT-31"
        }, 
        "intervention": {
            "arm_group_label": "1", 
            "description": "Inhaled Nitric Oxide will be delivered through the INOpulse\u00ae at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).", 
            "intervention_name": "Inhaled Nitric Oxide", 
            "intervention_type": "Drug", 
            "other_name": "INOmax\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Nitric Oxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 9, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "The Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "University of Colorado Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02903"
                    }, 
                    "name": "Rhode Island Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Development of a Hospital-Based Home Program for the Use of Inhaled Nitric Oxide in the Chronic Management of Severe Cardiopulmonary Diseases", 
        "overall_official": {
            "affiliation": "Children's Hospital Colorado", 
            "last_name": "Steven H Abman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Methemoglobin level", 
            "safety_issue": "Yes", 
            "time_frame": "24 and 72 hours after treatment start, then at 1, 3, 6, 9 and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041574"
        }, 
        "responsible_party": {
            "name_title": "Robert Small", 
            "organization": "INO Therapeutics"
        }, 
        "secondary_outcome": [
            {
                "measure": "Vital Signs", 
                "safety_issue": "Yes", 
                "time_frame": "taken at 1, 2, 3, 4, 24, and 72 hours after treatment begins, then at 1, 3, 6, 9 and 12 months"
            }, 
            {
                "measure": "Pulse Oximetry", 
                "safety_issue": "No", 
                "time_frame": "taken at 1, 2, 3, 4, 24, and 72 hours after treatment start and then at 1, 3, 6, 9 and 12 months"
            }, 
            {
                "measure": "Adverse Event Occurence", 
                "safety_issue": "Yes", 
                "time_frame": "Study Duration"
            }, 
            {
                "measure": "Echocardiogram", 
                "safety_issue": "No", 
                "time_frame": "At 72 hours after treatment start, then at 3, 6, 9 and 12 months"
            }
        ], 
        "source": "INO Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "INO Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2009", 
        "why_stopped": "Closed for lack of enrollment"
    }, 
    "geocoordinates": {
        "Rhode Island Hospital": "41.824 -71.413", 
        "The Children's Hospital": "39.739 -104.985", 
        "University of Colorado Hospital": "39.739 -104.985"
    }
}